SCHEMBL7684449

SCHEMBL7684449

CCC(Cl)Oc1ccc(-c2cn3cccc(C)c3n2)cc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.59
RAB9A P51151 8/20 0.57
NPC1 O15118 7/20 0.57
ALDH1A1 P00352 7/20 0.57
KDM4E B2RXH2 7/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NFKB1 P19838 3/20 0.57
NFKB2 Q00653 3/20 0.57
RELA Q04206 3/20 0.57
MAPT P10636 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
RECQL P46063 1/20 0.57
PKM P14618 1/20 0.54
GAA P10253 1/20 0.53
TP53 P04637 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
HSD17B10 Q99714 2/20 0.51
HPGD P15428 2/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411351 0.85 NPC1 (0.61) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL5413732 0.81 HRH3 (0.56) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL5414341 0.80 HRH3 (0.74) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL12797324 0.76 HRH3 (0.63) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL12797447 0.76 NPC1 (0.65) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL30309529 0.76 RAB9A (0.79) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL10547500 0.74 HRH3 (1.00) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL7678137 0.74 HRH3 (1.00) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL7675253 0.74 NPC1 (0.65) HRH3RAB9ANPC1ALDH1A1KDM4E
SCHEMBL7685361 0.73 RAB9A (0.67) HRH3RAB9ANPC1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6489337-B1 TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-12-03 US disclosed
WO-2001074813-A2 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed